Sign in →

Search

 

 

Altru's Laboratory is a College of American Pathologists (CAP) accredited, high complexity laboratory. The laboratory serves northeastern North Dakota and northwestern Minnesota, and operates and advises several regional clinic laboratories. We also provide outreach laboratory services to non-Altru health facilities in the region.

 

The main laboratory is in operation 24 hours a day, 7 days a week, 365 days a year. There are pathologists       on-site with anatomic and clinical pathology board certifications. Laboratory staff includes medical laboratory scientists, medical laboratory technicians, lab assistants, phlebotomists, histotechnologists, and cytotechnologists.

 

Altru Pathology and Laboratory Services

1200 South Columbia Road

Grand Forks, ND 58201

701.780.5130 /Fax 701.780.1473

 

___________________________________________________________________________________________________

 

NEW MAYO TESTS AVAILABLE:

 

In October 2017, Mayo Medical Laboratories announced the following new tests.

  • CNS Demyelinating Disease Evaluation, Serum (ID: CDS1) Useful for: Diagnosis of inflammatory demyelinating diseases (IDDs) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis; Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy; Diagnosis of neuromyelitis optica (NMO); Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease; Diagnosis of ADEM; Prediction of a relapsing disease course

 

  • Dihydropyrimidine Dehydrogenase (DPYD) Genotype (ID: DPYDV) Useful for:Identifying individuals with genetic variants in DPYD who are at increased risk of toxicity when prescribed 5-fluorouracil (5-FU) or capecitabine chemotherapy treatment
     
  • Focused Pharmacogenomics Panel (ID: PGXFP) Useful for: Preemptive or reactive genotyping of patients for pharmacogenomic purposes; Providing an assessment for genes with strong drug-gene associations
     
  • Myelin Oligodendrocyte Glycoprotein (MOG-IgG1) Fluorescence-Activated Cell Sorting (FACS) Assay, Serum (ID: MOGFS) Useful for: Diagnosis of inflammatory demyelinating diseases (IDD) with similar phenotype to neuromyelitis optica spectrum disorder (NMOSD), including optic neuritis (single or bilateral) and transverse myelitis; Diagnosis of autoimmune myelin oligodendrocyte glycoprotein (MOG)-opathy; Diagnosis of neuromyelitis optica (NMO); Distinguishing NMOSD, acute disseminated encephalomyelitis (ADEM), optic neuritis, and transverse myelitis from multiple sclerosis early in the course of disease; Diagnosis of ADEM; Prediction of a relapsing disease course
     
  • Neuromuscular Genetic Panels by Next-Generation Sequencing (NGS) (ID: NMPAN) Useful for: Establishing a diagnosis of a neuromuscular disorder associated with known causal genes; Serving as a second-tier test for patients in whom previous targeted gene mutation analyses for specific inherited neuromuscular disorder-related genes were negative; Identifying mutations within genes known to be associated with inherited neuromuscular disorders, allowing for predictive testing of at-risk family members;

 

  • SERPINA1 Gene, Full Gene Analysis (ID: SERPZ) Useful for: Identification of causative mutations when a deficient serum level of alpha-1-antitrypsin is not explained by routine testing, such as proteotyping, genotyping, or isoelectric focusing phenotyping; Determining the specific allelic variant (full gene analysis) for prognosis and genetic counseling
     
  • Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15) Genotyping (ID: TPNUV) Useful for: Predicting potential for toxicity to thiopurine drugs (6-mercaptopurine, 6-thioguanine, and azathioprine)
     
  • Warfarin Response Genotype (ID: WARSV) Useful for:

    Identifying patients who may require warfarin dosing adjustments(3,4) including:

    -Patients being started on a first prescription for warfarin

    -Patients who have previously been prescribed warfarin and have required multiple dosing adjustments to maintain the international normalized ratio in the target range

    -Patients with a history of thrombosis or bleeding when taking warfarin